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Introduction: There are an estimated 60,000 new cases of ductal carcinoma in situ (DCIS) each year. A lack of
understanding in DCIS pathobiology has led to overtreatment of more than half of patients. We profiled the temporal
molecular changes during DCIS transition to invasive ductal carcinoma (IDC) using in vivo DCIS progression models.
These studies identified B cell lymphoma-9 (BCL9) as a potential molecular driver of early invasion. BCL9 is a newly
found co-activator of Wnt-stimulated β-catenin-mediated transcription. BCL9 has been shown to promote progression
of multiple myeloma and colon carcinoma. However BCL9 role in breast cancer had not been previously recognized.
Methods: Microarray and RNA sequencing were utilized to characterize the sequential changes in mRNA expression
during DCIS invasive transition. BCL9-shRNA knockdown was performed to assess the role of BCL9 in in vivo invasion,
epithelial-mesenchymal transition (EMT) and canonical Wnt-signaling. Immunofluorescence of 28 patient samples was
used to assess a correlation between the expression of BCL9 and biomarkers of high risk DCIS. The cancer genome
atlas data were analyzed to assess the status of BCL9 gene alterations in breast cancers.
Results: Analysis of BCL9, by RNA and protein showed BCL9 up-regulation to be associated with DCIS transition to IDC.
Analysis of patient DCIS revealed a significant correlation between high nuclear BCL9 and pathologic characteristics
associated with DCIS recurrence: Estrogen receptor (ER) and progesterone receptor (PR) negative, high nuclear grade,
and high human epidermal growth factor receptor2 (HER2). In vivo silencing of BCL9 resulted in the inhibition of DCIS
invasion and reversal of EMT. Analysis of the TCGA data showed BCL9 to be altered in 26 % of breast cancers. This is a
significant alteration when compared to HER2 (ERBB2) gene (19 %) and estrogen receptor (ESR1) gene (8 %). A
significantly higher proportion of basal like invasive breast cancers compared to luminal breast cancers showed BCL9
amplification.
Conclusion: BCL9 is a molecular driver of DCIS invasive progression and may predispose to the development of basal
like invasive breast cancers. As such, BCL9 has the potential to serve as a biomarker of high risk DCIS and as a therapeutic
target for prevention of IDC.* Correspondence: fbehbod@kumc.edu
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Ductal carcinoma in situ (DCIS) is a complex pathologic
condition in which malignant breast epithelial cells prolif-
erate inside the ducts but do not invade the surrounding
stroma. Modern screening technologies have made DCIS a
more common diagnosis than in the past. Insufficient un-
derstanding of DCIS biology has limited advances in ther-
apy. For example, can a subset of DCIS patients be safely
monitored with watchful waiting, as has been adopted for
certain prostate cancers in men? As it now stands, a large
proportion of patients with DCIS are overtreated, as it is
estimated that only 25 − 50 % of cases would progress to
invasive cancer over time if left untreated [1–3]. Given the
current understanding of DCIS, it remains challenging to
reliably stratify DCIS lesions with appropriate sensitivity
and specificity to predict progression to invasion [3]. The
aim of our study is to identify key molecular mechanisms
underlying DCIS progression to invasive ductal carcinoma
(IDC) and to assess their potential as future predictive bio-
markers of high-risk DCIS. Ultimately, the ability to separ-
ate DCIS lesions into high vs low risk will advance the
field, our understanding of DCIS and ultimately eliminate
overtreatment.
It was generally agreed that the molecular profiles of
DCIS and IDC were similar and that the genetic program
necessary for invasive progression might already exist in
the pre-invasive stages of breast cancer [4, 5]. However,
there are other conflicting reports making this area of re-
search worth further exploration. For example, one study
suggested that there may be gene dosage changes during a
transition from DCIS to IDC [6]. Liao and colleagues
found differential genomic copy number aberrations in
DCIS with an invasive potential compared to pure DCIS by
array comparative genomic hybridization (aCGH) [7]. An-
other study found amplification of distinct loci restricted to
a specific population of cancer cells in 3 out of 13 matched
DCIS − IDC pairs [8]. Collectively, these latter studies
suggest that unique genomic aberrations in some can-
cer cells or distinct population of cancer cells may drive
DCIS to IDC.
In this study, sequential and temporal changes in gene
expression during DCIS invasive progression have been
characterized by utilizing two systems: DCIS cell line-
derived mouse intraductal (MIND) xenograft models
(SUM225 and DCIS.COM) and a tandem DCIS/IDC
model that uses samples from patients afflicted with DCIS
that are synchronous with IDC within the same breast. Both
models involve DCIS non-invasive to invasive transition and
provide valuable tools for studying the temporal molecular
changes associated with DCIS invasive transition.
The MIND is a novel DCIS in vivo model that has been
developed by our group [9]. MIND involves injection of
DCIS cell lines or cells derived from primary patient DCIS
within the mammary ducts of immunocompromised mice.MIND xenotransplantation is a realistic human DCIS
model because it mimics the entire process of DCIS
progression, including ductal growth as in situ lesions
followed by their invasion as they escape the natural
barriers of normal myoepithelial cells and the basement
membrane. As previously reported by our group [9],
DCIS.COM MIND xenografts generate basal-like le-
sions and become invasive by 10 weeks post-injection,
whereas those generated by the SUM225 cells generate
human epidermal growth factor 2 (HER2) over-expressing
luminal lesions that invade the myoepithelial layer by 14
weeks. The second model includes tandem DCIS/IDC le-
sions. The lesions are identified radiologically by an area
of clustered microcalcifications adjacent to (contiguous
with) an invasive mass and sampled by core biopsy. For
these studies, six pairs were collected and analyzed by
RNA sequencing for differential gene expression com-
paring DCIS to the corresponding IDC.
Molecular profiling of both in vivo DCIS progression
models revealed a significant increase in BCL9 mRNA
and protein expression when comparing non-invasive to
invasive lesions in our DCIS cell line MIND xenografts
and in five out of six DCIS/IDC tandem lesions. BCL9 is
a recently identified Wnt pathway activator, which has
been shown to play an important role in transcriptional
activity of β-catenin in association with lymphoid enhancer-
binding factor 1 (LEF)/T cell specific (TCF) family members
[10]. BCL9 has been shown to play a critical role in progres-
sion of colorectal cancers and multiple myeloma by activa-
tion of Wnt oncogenic signaling [11]. However, the role of
BCL9 in mammary gland biology and breast cancer has not
been explored previously. In this manuscript, we provide
evidence that BCL9 serves as a molecular driver of epithelial
mesenchymal transition (EMT) and DCIS invasion by the
enhancement of canonical Wnt signaling. Therefore, BCL9
may serve as a potential biomarker of high-risk DCIS, guid-
ing appropriate therapy for these lesions and reducing over-
all overtreatment of other DCIS lesions that are more
indolent. Furthermore, BCL9 promises to serve as a
therapeutic target for prevention of IDC.
Methods
Animals and animal surgery
Mouse surgery was performed on 8- to 10-week-old vir-
gin female NOD-SCID IL2Rgamma null (NSG) mice that
were either bred or purchased from Jackson Laboratories
(Bar Harbor, ME, USA) as previously described [9]. Ani-
mal experiments were conducted following protocols ap-
proved by the University of Kansas School of Medicine
Animal Care.
Cell culture
DCIS.COM and SUM225 were purchased from Aster-
and, Inc. (Detroit, MI, USA) in 2007 and were maintained
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been authenticated by genomic profiling validating the es-
trogen receptor-negative, progesterone receptor-negative,
HER2-positive (ER- PR- HER2+) status of the SUM225 cells
and the ER- PR- HER2- expression pattern in the DCIS.-
COM [12].
Tandem lesion biopsies
All human experiments were approved by the University of
Kansas Medical Center Institutional Review Board (IRB).
All patients gave written informed consent for participation
in this research. Subject recruits included patients undergo-
ing image-guided core needle biopsy due to suspicion of
DCIS or IDC. In all cases, research specimens were ob-
tained only after acquisition of diagnostic specimens. Our
radiologists apply minimally invasive ultrasound-guided se-
lective tissue harvest of contiguous lesions with a tandem
appearance and provide us with biopsy cores from each re-
gion. Biopsy tissue was placed in preservation media (Lifor-
Cell, Lifeblood Medical, Inc., Freehold, NJ, USA) and stored
at 4 °C on ice until RNA isolation.
Patient samples for analysis of BCL9 as a potential
biomarker of high risk
Tissue sections for BCL9 analysis were provided by Dr.
Jeffrey Marks (Duke University) as a part of the NIH
Early Detection Research Network (EDRN) GYN/Breast
Working Group Initiative to validate biomarkers that
may predict a greater risk of invasive breast cancer or
worst-prognosis disease. These samples were identified,
procured, and sectioned, stored and maintained under a
Duke-approved protocol (eIRB Pro00027811, J Marks,
PI). Two categories were defined: cases of DCIS that
progressed to invasive cancer in the same breast be-
tween 1.8 and 17.6 years after initial diagnosis and con-
trols with DCIS that did not progress (either recurrent
DCIS or invasive cancer) over a minimum of 10 years
follow up. Controls were further selected based on size
and nuclear grade to match or exceed the sizes in the
cases. The Van Nuys index [13] for controls had a
higher median value than the cases (p = 0.04).
RNA isolation, quantitative PCR (qPCR) and wnt target
qPCR arrays
Total RNA was isolated with miRNeasy Mini Kit
(Qiagen #217004, QIAGEN Inc., Valencia, CA, USA)
using the manufacturer’s protocol, and cDNA was
synthesized from 250 ng of total RNA with miScript
Reverse Transcription Kit (Qiagen #218061). TaqMan® Gene
Expression Master Mix (Applied Biosystems #4369016)
and TaqMan® Gene Expression assays were used.
Primers specific for human BCL9 (Applied Biosystems
#Hs00979216_m1) were utilized and target gene expression
was normalized to human β-actin (Applied Biosystems#Hs99999903_m1). The standard curve method was used
for quantification. Reactions were performed in the
StepOnePlus™ Real-Time PCR system and software
(Applied Biosystems, part of Thermo Fisher Scientific,
Waltham, MA, USA) in 96-well plates. The data were ana-
lyzed using the ΔΔ cycle threshold (CT) method [14].
Statistical analysis
Data are presented as mean normalized expression ±
standard error of the mean (SEM). Unless otherwise
noted, one-way analysis of variance (ANOVA) was used
for statistical comparisons. A value of p ≤0.05 was
considered significant.
Microarray gene expression profiling and analysis
We utilized DCIS MIND models, a novel model devel-
oped in our laboratory, which most closely mimics the
human DCIS environment, with both SUM225 and
DCIS.COM cell lines to characterize the sequential and
temporal changes in mRNA expression over a time
course of 2, 6, and 10 weeks during in vivo progression
in the epithelial cells. Microarray technology was utilized
to analyze gene expression profiles from RNA isolated
from magnetically sorted epithelial cells from MIND xe-
nografts at 2, 6 and 10 weeks post-injection. For these
studies, five mice per replicate (three replicates) per time
point (three time points; 2, 6, and 10 weeks) for each cell
line (two cell lines; DCIS.COM and SUM225) were used.
The mammary epithelial cells were magnetically sorted
from five mice at each time point per replicate. After
sorting, Qiazol extraction of total RNA was performed
according to the manufacturer’s instructions. Labeling
was performed using the GeneChip 3' IVT Express Kit
(Affymetrix, Santa Clara, CA, USA), which utilizes an
oligo dT-based reverse transcription reaction followed
by a T7 promoted in-vitro transcription biotin labeling
reaction. Hybridization was performed using the Gene-
Chip Hybridization, Wash and Stain Kit (900720). The
platform used is HG-U133_Plus_2 Affymetrix Human
Genome U133 Plus 2.0 Array. GeneChips were scanned
using the Affymetrix GeneChip Scanner 3000 7G. Raw
mRNA expression values from the 2-week, 6-week and
10-week samples were normalized and converted to
the log2 scale. Data were median-centered and analyzed
by unsupervised average-linkage hierarchical clustering
using Cluster 3.0 software [15]. The computed data matrix
was then uploaded into Java TreeView software and visual-
ized as a heat map [16]. Clustering of expression data
from DCIS.COM and SUM225 cell lines revealed that
the majority of expression changes had already occurred
at the 6-week time point with little change occurring be-
tween 6 and 10 weeks. This suggests that mechanisms of
invasion are already in place by week 6. Further analysis
was focused on the 2-week to 6-week time point.
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utilized to determine differentially expressed genes between
the 2-week and 6-week time point in both DCIS.COM and
SUM225 cell lines [17]. The cutoff for significance was de-
termined by <5 % false discovery rate (FDR). Two-class un-
paired SAM analysis generated a list of significant genes
and fold-change values between 2 and 6 weeks in DCIS.-
COM (18,590 downregulated; 10,227 upregulated) and
SUM225 (19,953 downregulated and 14,691 upregulated).
These genes were further analyzed using QIAGEN Ingenu-
ity® Pathway Analysis (IPA®, QIAGEN Redwood City, [18]).
IPA software integrates expression changes with known
molecular interactions and disease processes [19]. The
Wnt/β-catenin canonical pathway was identified as a sig-
nificantly upregulated pathway in both cell line MIND xe-
nografts during transition from 2 to 6 weeks. The raw and
analyzed microarray data have been deposited in the NCBI
Gene Expression Omnibus and are accessible through
GEO [GEO:GSE65890] [20].RNA sequencing and analysis
Total RNA was prepared using the All prep Qiagen Kit,
according to the manufacturer’s protocol. Libraries were
prepared by illumina TruSeq RNA Sample Preparation Kit
(A cat#FC-122-1001, B cat#FC122-1002) according to the
manufacturer’s protocol. Libraries were prepared using illu-
mina TruSeq RNA Sample Preparation Kit (A cat#FC-122-
1001, B cat#FC122-1002) according to the manufacturer’s
protocol. The DCIS and IDC samples were sequenced
using a HiSeq2500 2 × 100 bp version 3 sequencing
run. Eight sample libraries were multiplexed, four per
lane resulting in 46.9X – 58.2X coverage per sample.
Four sample libraries were multiplexed, two per lane result-
ing in 107.4X – 124X coverage per sample. Paired Fastq se-
quence files were imported to CLC Genomics Workbench
(version 7.5) and mapped to the human reference genome
(hg19) using the approach previously described [21]. The
Ensembl database (GRCh37.74.gtf) was used for gene an-
notation. Total number of reads mapped to the gene was
used as the total counts for the gene, and the values were
transformed by adding 1 followed by log2 transformation.
Transformed data were quantile-normalized before the
analysis of differential gene expression between two groups
(DCIS vs IDC). Empirical analysis of differential gene ex-
pression was performed between two groups (DCIS vs
IDC) using the exact test as previously described [22].
The raw and analyzed RNA sequencing data have been
deposited in the NCBI Gene Expression Omnibus and are
accessible through GEO [GEO:GSE66301] [23].The Cancer Genome Atlas (TCGA) data analysis
All TCGA RNASeqV2 breast cancer data (*rsem.genes.re-
sults) were downloaded from TCGA data portal [24]. In R[22, 25–26] the raw counts were normalized for at least 5
counts in at least 113 (number of normal samples). The
normalized counts for the gene BCL9 were obtained and
log transformed. All cancer samples with BCL9 levels
above the range defined by normal samples were la-
beled UP regulated in cancer (414). Differential gene
expression was performed between cancer samples with
a normal range of BCL9 and samples with upregulated
BCL9. A list of significant genes (1,756 downregulated, 980
upregulated) was obtained with a threshold of FDR ≤0.05
and log fold change 0.26. The significant genes were ana-
lyzed in IPA and the Canonical Wnt with a p value ≤0.05
was shown to be among the significantly altered pathways.
Immunofluorescence staining (IF)
IF was performed as previously described [27]. Antibodies
are listed in Additional file 1: Table S1. Nuclei were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI;
Vector Laboratories, # H-1200, Vector Laboratories, Inc,
Burlingame, CA, USA). Negative controls were carried out
using secondary antibodies without the primary antibodies.
Imaging was performed on a laser-scanning confocal
microscope (Model 510; Carl Zeiss MicroImaging, Inc,
Thornwood, NY, USA). The acquisition software used was
Pascal (Carl Zeiss MicroImaging, Inc). Fluorescence quanti-
tation and analysis was done using ImageJ [28]. Images
were analyzed for area of selection, mean gray value, and
integrated density. Both the areas of interest and their back-
ground were measured, then the corrected total cell fluor-
escence (CTCF) was calculated by the following formula:
CTCF ¼ Integrated density–Area of selected cells
 Mean fluorescence of background readings:
Plasmids, transfection, and luciferase reporter assay
Plasmid constructs: pSuper8X–TOPFlash reporter (Addgene
plasmid 12456, Addgene, Cambridge, MA, USA) and Super
8x FOPFlash (TOPFlash mutant) (Addgene plasmid 12457)
were provided by Randall Moon via Addgene [29, 30].
Renilla luciferase plasmid phRG was from Promega. The
β-catenin△N (Addgene plasmid 19288) construct was
acquired from Eric Fearon via Addgene [30]. PCDH-
BCL9 (BCL9-OE), PLKO.1-BCL9-shRNA (BCL9KD)
(CCTCTGTTGAATATCCCTGGAA) and PLKO.1-non-
silencing control (Control) were acquired from Dr. Carrasco
[11]. pGIPZ Human BCL9 shRNA (BCL9 KD 2)
(TGCAAACTTGGACATTCGA), and pGIPZ-non-silencing
control (Control 2) were obtained from Dharmacon
(#RHS4430-200265260). Transfection: DCIS.COM and
SUM225 were transfected with electroporation using
Amaxa ™ Cell line Nucleofector kit V (Lonza #VCA-1003,
Lonza Group Ltd, Basel, Switzerland), while HEK293T
cells were transfected using Lipofectamine 2000 reagent
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Scientific, Waltham, MA, USA) according to manu-
facturer’s protocols. Luciferase assay was performed
using Dual-Luciferase® Reporter Assay System (Promega
#E1910, Promega Corporation, Madison, WI ,USA).
Lentivirus production
Glycerol stocks of pLKO.1 shRNA-based BCL9 and PLKO.1
non-silencing control were cultured in the presence of
100 μg/ml of ampicillin (Amresco # 0339, AMRESCO LLC,
Solon, OH, USA) and plasmids were purified using HiSpeed
Plasmid midi kit (Qiagen #12643). Preparation of viral
particles were performed by co-transfecting individual
pLKO.1 vectors (10 μg), packaging plasmid pCMV-dR8.2
(contains Gag, Pol, Rev, and Tat) (Addgene plasmid
8455; 5 μg), and the envelope plasmid pCMV-VSVG
(Addgene plasmid 8454; 5 μg) in HEK293T cells. Both
plasmids were acquired from Robert Weinberg via
Addgene [31]. Transfection was performed in a 10-cm
plate, nearly 75 % confluent using Lipofectamine 2000
transfection reagent (Invitrogen #11668-027) in antibiotic
free Opti-MEM media (Invitrogen #51985-034) following
the manufacturer’s protocol. Media was collected after 48,
72, and 96 h of transduction, pooled and subjected to
ultracentrifugation at 80,000 × g for 2 h (Beckman Coulter,
Optima L-100 XP, 70Ti rotor). The pellets of the concen-
trated viral particles were re-suspended in 250 μl of
DMEM (GIBCO #21063029, GIBCO, part of Thermo
Fisher Scientific, Waltham, MA, USA), and stored in
aliquots at −80 °C until further use. Lentiviral titers were
measured using Lenti-X™ p24 Rapid Titer kit (Clontech
#632200, Clontech, Mountain View, CA, USA). Transduc-
tion was performed at an Multiplicity of infection (MOI)
of 3 and 20 for DCIS.COM and SUM225, respectively,
and cells continued to grow in the presence of puromycin
(Thermo Scientific #100552, Thermo Scientific, part of
Thermo Fisher Scientific, Waltham, MA, USA). For vari-
ous experiments, transduced cells from up to five passages
were used.
MTS, invasion and migration assays
For MTS assays, Cell Titer 96® Aqueous Non-Radioactive
Cell Proliferation Assay (Promega #G5421) was used ac-
cording to the manufacturer’s protocol. Transwell assays
were used to measure invasion and migration. The upper
side and underside of the transwells (Corning #3422,
Corning, Inc, Corning, NY, USA) were coated with
Corning™ Matrigel™ Membrane Matrix (Fisher Scientific
#CB-40230) (1 mg/ml in serum-free media) for the
invasion assay, and with Corning™ Human Fibronectin
(Fisher scientific #CB-40008, Fisher Scientific, part of
Thermo Fisher Scientific, Waltham, MA, USA) (50 μg/ml
PBS/0.1 % gelatin) for the migration assay. DCIS.COM
and SUM225 cells were starved of serum for 24 h prior touse. Cells were irradiated at 10 gray and 2.5 × 104 cells
were plated in serum-free media in the upper well. The
percent area of migration and invasion were analyzed
in DCIS.COM and SUM225 cells after 24 and 96 h,
respectively. Invasion and migration were determined
by ImageJ [28] analysis of microscopic images.
For in vivo invasion studies, BCL9-KD, non-transduced
(NT), and scrambled shRNA control (control) SUM225
and DCIS.COM cells were injected at 10,000 cells per
gland. A total of three glands and three animals in control
groups, five glands and four animals in KD groups and
four glands in four animals in NT groups were examined.
The glands were collected at 10 and 14 weeks post-
intraductal injection in DCIS.COM and SUM225 xeno-
grafts, respectively. The mammary glands containing DCIS-
like lesions were then fixed, embedded and sectioned at
5 μm. Every tenth section was stained with H&E to
identify the sections with the greatest xenograft growth
for each gland. Then four sections adjacent (two sec-
tions on each side) to the one with the greatest growth
were prepared for IF as described above, stained for
human-specific K5/K19, SMA and counterstained with
DAPI. Imaging was performed as described above.
Invasive lesions were identified by the lack of a smooth
muscle actin (SMA)-expressing myoepithelial layer. The
LSM image browser was used to measure the maximum
distance of an invasive lesion to the closest DCIS lesion in
each section. To determine the number of invasive lesions
per section, confocal images (×20 magnification) were
taken of all invasive lesions and counted. Measurements
(i.e., distance of invasion and number of invasive lesions)
for the four sections were averaged to represent each gland.
Data are presented as the maximum distance of invasion
(μm) and number of invasive areas in each section.
Western blot analysis and co-immunoprecipitation
For co-immunoprecipitation, 1,000 μg of protein was
incubated with antibodies at 4 oC overnight followed by
centrifugation at 3,000 rpm for 1 minute in 4 oC. The su-
pernatants were incubated with Protein A/G PLUS-Agrose
beads (Santa Cruz #sc-2003, Santa Cruz Biotechnology,
Inc., Dallas, Texas, USA) at 4 °C for 1 h, followed by a wash
in PBS. Proteins bound to the beads were eluted with SDS-
loading buffer at 99 °C for 5 minutes and then loaded for
western blot, and 2 μg of whole cell lysates were loaded as
input. Western blots analysis was carried out as previously
described [32]. For western blots, 25 μg of DCIS.COM and
50 μg of SUM225 cell lysates were loaded into each lane.
The antibodies used are listed in Additional file 1: Table S1.
FACS analysis and magnetic sorting
The cells were stained at a final concentration of 1∶20
for 30 minutes on ice followed by washes in Hanks’
Balanced Salt Solution (Invitrogen #24020-117) containing
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Fig. 1 (See legend on next page.)
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Fig. 1 Differentially expressed genes in DCIS.COM and SUM225 mouse intraductal xenograft models (MIND). a The MIND model. MIND xenografts
were generated by intraductal injection of DCIS.COM and SUM225 cells into the mammary ducts of immunocompromised mice. Mammary glands
containing DCIS-like lesions were collected at the distinct stages of in situ to invasive lesions (2, 6 and 10 weeks) followed by digestion,
magnetic sorting of epithelial cells and RNA isolation. The RNA was subjected to microarray analysis. b Heatmap of differentially expressed genes
in DCIS.COM and SUM225 MIND xenografts at 2, 6 and 10 weeks. Unsupervised average-linkage hierarchical clustering of expression data
from DCIS.COM and SUM225 MIND xenografts revealed that the majority of expression changes occurred at the 2-week to 6-week time
point with little change occurring from 6 to 10 weeks. Further analysis was focused on the 2-week to 6-week time points. c, d Heatmap of differentially
expressed genes in the canonical Wnt pathway from 2 to 6 weeks in DCIS.COM (c) and SUM225 (d) MIND xenografts. Unsupervised average-linkage
hierarchical clustering was used to visualize significantly upregulated or downregulated genes in the WNT pathway, using a cutoff false discovery rate
of <5 %
Elsarraj et al. Breast Cancer Research  (2015) 17:128 Page 7 of 212 % fetal bovine serum. The antibodies used are listed in
Additional file 1: Table S1. FACS and data analysis were
performed using the BD LSR II flow cytometer and FlowJo
software (Tree Star). Magnetic sorting was performed
using Easy Sep® human Epcam positive selection kit (Stem
Cell Technology #18356, STEMCELL Technologies Inc.,
Vancouver, BC, Canada) according to the manufacturer’s
protocol.
Results
BCL9 upregulation is associated with DCIS epithelia that
progress to invasion
In order to explore the temporal molecular changes asso-
ciated with DCIS non-invasive to invasive transition, we
utilized our DCIS cell line MIND models and DCIS/IDC
tandem lesions. The mammary glands containing DCIS-
like lesions were excised followed by digestion to isolate
the epithelial cell components at three time points: 2, 6
and 10 weeks post-injection. These time points were se-
lected in order to accurately reflect the molecular changes,
as the DCIS lesions are formed between 2 and 6 weeks
and progressed past the myoepithelial layer and the base-
ment membrane by 10 weeks (Fig. 1a). In order to separ-
ate human DCIS epithelial cells from mouse mammary
cells, EpCAM-positive cells were magnetically sorted
followed by RNA isolation and microarray analysis.
The majority (>90 %) of DCIS.COM and SUM225 cells
express EpCAM, Additional file 2: Figure S1. Additionally,
we performed RNA sequencing of patient DCIS/IDC tan-
dem lesion pairs. A heatmap of analyzed microarray data is
shown in Fig. 1b-d, and the differentially expressed genes
are shown in Additional file 3. We focused our analysis on
the canonical Wnt signaling, because a recent report by
Scheel and colleagues demonstrated that the collabor-
ation of three signaling pathways, transforming growth
factor beta (TGF-β), canonical and non-canonical Wnt
signaling induced and maintained an EMT state in mam-
mary epithelial cells [33]. Acquisition of an EMT-like pheno-
type is believed to be the initiating event prior to cell
invasion. An EMT-like phenotype can result from an
aberrant basal differentiation program in differentiated
luminal/epithelial cells or in stem/progenitor cells [34].
Furthermore, this study showed that pre-treatment ofepithelial cells with the Wnt activators followed by TGF-β
and downregulation of E-cadherin resulted in a synergistic
enhancement in EMT and cellular migration. These data
suggest that Wnt signaling is the earliest event in the
process of EMT and cellular invasiveness. We decided to
concentrate on one of the genes in the canonical Wnt sig-
naling pathway, B cell lymphoma-9 (BCL9), because it was
found to serve as a co-factor of β-catenin in early
2000 [35], however, there were no previous studies on
the role of BCL9 in breast cancer. BCL9 is located on
chromosome 1q21, a common amplified region in breast
cancer. Analysis of the microarray data of the MIND sam-
ples showed canonical Wnt signaling to be among the sig-
nificantly upregulated pathways in our dataset (Fig 1c-d,
Additional file 4) and BCL9 was significantly upregulated
during the transition from DCIS to IDC (q value <5 %)
(Fig. 1c-d and Additional file 3). We also assessed BCL9
expression in six pairs of DCIS/IDC tandem lesions by
RNA sequencing. Tandem DCIS/IDC are defined as DCIS
lesions that have concurrent IDC within the same breast
(Fig. 2a-c). The analysis of tandem lesion RNA sequencing
data for BCL9 expression comparing DCIS to IDC is shown
in (Fig. 2d-e). This analysis showed a significant upregula-
tion in BCL9 expression in the IDC component compared
to DCIS (Fig. 2a-e).
To confirm our microarray analysis, RT-qPCR was per-
formed on EpCAM-positive cells sorted from an inde-
pendent set of DCIS cell line MIND xenografts as they
progressed from 2 to 10 weeks. BCL9 gene expression was
significantly increased at 10 compared to 2 weeks in both
SUM225 and DCIS.COM MIND xenografts (62 ± 14 and
35 ± 12 fold increase, respectively; mean ± SEM p <0.05)
(Fig. 3a, b). Furthermore, IF staining of the MIND xeno-
grafts demonstrated increased nuclear BCL9 expression as
DCIS lesions progressed to invasion (Fig. 3c, d). There
have been a few reports on the role of BCL9L (BCL9-2 or
B9L), BCL9 homolog, in breast cancer. One study showed
nuclear BCL9L expression to be significantly associated
with high nuclear grade and the expression of HER2 in
breast cancers [36]. Another study reported that BCL9L
induced ER positive breast cancers in vivo by regulating
the expression of ER through a β-catenin independent
mechanism and predicted therapeutic response to
DCIS IDC
A CB
D
E
Fig. 2 Analysis of RNA sequencing data of tandem lesions for BCL9 expression comparing DCIS to invasive ductal carcinoma. Radiographic
(a) and H&E stain (b, c) images of a patient’s DCIS/IDC tandem lesion. a Three-dimensional ultrasound image of a tandem lesion. b H&E staining
of a biopsy taken from the DCIS and (c) the IDC regions. Insets: lower magnification in b, c, respectively, demonstrating that the biopsies were
highly pure and composed of either DCIS or IDC. d, e Normalized log2 transformed expression of BCL9 was plotted and tandem lesions between
paired DCIS and IDC are connected by a line to indicate their relationship. The results indicate a significant increase in BCL9 expression in IDC
samples compared to the DCIS lesions (p = 0.01)
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reside on chromosome 1q21 and 11q23.3 respectively.
Both BCL9 and BCL9L have been shown to function as
co-activators of β-catenin-LEF/TCF mediated transcrip-tion [38, 39]. We compared the expression patterns of
BCL9 and BCL9L in DCIS cell line MIND xenografts and
on tissue sections obtained from 23 patients with DCIS
and associated IDC and 14 patients with pure DCIS.
D
C
IS
.c
om
10 weeks6 weeks2 weeks
S
U
M
22
5
B
0
10
20
30
40
50
60
2 weeks 6 weeks 10 weeks
DCIS.COM
*
0
10
20
30
40
50
60
70
80
2 weeks 6 weeks 10 weeks
F
o
ld
 C
h
an
g
e 
in
 B
C
L
9/
b
-A
ct
in
ex
p
re
ss
io
n
 n
o
rm
al
iz
ed
 t
o
 2
 w
ee
ks
F
o
ld
 C
h
an
g
e 
in
 B
C
L
9/
b
-A
ct
in
ex
p
re
ss
io
n
 n
o
rm
al
iz
ed
 t
o
 2
 w
ee
ks
SUM225
*
A
BCL9
DAPI
K5
BCL9
DAPI
K19
C
D
Fig. 3 Enhanced BCL9 nuclear expression in DCIS cell line MIND xenografts that progressed to invasive lesions. a, b RT-qPCR of BCL9 in epithelial cell adhesion
molecule (EpCAM)-positive epithelial cells sorted from SUM225 (a) and DCIS.COM (b) MIND xenografts at 2, 6, and 10 weeks post-intraductal injection. Bar
graphs represent fold change normalized to 2 weeks. Data are mean values ± standard error of the mean (n = 3, *p <0.05). c, d Immunofluorescent (IF)
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Scale bars are 50 μm; × 40 objective was used
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sion was mainly cytoplasmic, while BCL9 expression was
primarily nuclear. Furthermore, RT-qPCR showed no
significant increase in BCL9L expression in DCIS
MIND xenografts during invasive transition from 2 to
10 weeks (Additional file 5: Figure S2B-C). Western
blot on cell lysates obtained from DCIS cell lines also
showed no change in BCL9L expression with BCL9
KD. Therefore, the results in both the MIND and
tandem lesions support the hypothesis that increased
BCL9 expression is associated with DCIS transition to
invasion, while our data do not show a change in
BCL9L expression associated with DCIS progression.
BCL9 knockdown (KD) inhibits the proliferative, migratory,
and invasive activity of DCIS cells in vitro and in vivo
The canonical Wnt pathway is required for normal devel-
opment and tissue homeostasis [40]. However, aberrant
activation of canonical Wnt signaling has been implicated
in the development and progression of many cancers
including breast cancer [41, 42]. BCL9 overexpression has
been proposed as one mechanism that may contribute to
the aberrant Wnt activation [11]. BCL9 possesses a potenttranscription activation domain and might function as an
oncogene by providing an alternative pathway for β-catenin
activation and subsequent tumor progression [35].
To assess the role of BCL9 in promotion of DCIS in-
vasive progression, two shRNA-based BCL9 constructs
have been utilized: shRNA1 [11] and shRNA2, as well as
their corresponding scrambled controls (Control 1 and
Control 2). As the values for NT and scrambled shRNA
(control) were similar in all of the experiments, only the
values for the shRNA control groups are listed in the
results section. Western blot confirmed that shRNA1
efficiently knocked down BCL9 in both DCIS.COM
(Fig. 4a; left panel) and SUM225 (Fig. 4a; right panel).
We have also demonstrated efficient BCL9 KD using
shRNA2 (Additional file 6: Figure S3A). MTS assay was
performed to assess the role of BCL9 on cell growth
in vitro (Fig.4b and Additional file 6: Figure S3B). As shown
in Fig. 4b, BCL9 KD significantly suppressed growth by
0.55 ± 0.01 fold (p <0.05; compared to 1.02 ± 0.02 in
control) in DCIS.COM and by 0.62 ± 0.01 fold in
SUM225 (p <0.05; compared to 0.76 ± 0.004 in control).
To assess the role of BCL9 on cell migration and inva-
sion, fibronectin and reconstituted basement membrane
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Fig. 4 BCL9-KD decreased proliferative, migratory and invasive activity of DCIS cell lines in vitro. a Western blot analysis using anti-BCL9 antibody and
anti-β-actin as a loading control (top), and (b) MTS assays of non-transduced (NT), scrambled control (control) and BCL9-KD in DCIS.COM (left panels)
and SUM225 (right panels). Bar graphs represent mean absorbance at 490 nm normalized to NT ± standard error of the mean (SEM) (n = 3, * p <0.05).
c, d Representative images of the migration and invasion assays. Bar graphs represent percent area of cells migrated (top) and invaded (bottom) under
the membrane after 24 h for DCIS.COM and 96 h for SUM225. Invasion and migration were determined by ImageJ analysis of microscopic images per
sample, the data are mean values normalized to NT ± SEM (n = 3, * p <0.05)
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BCL9 KD reduced invasion of DCIS.COM cells (0.23 ± 0.03
fold, p <0.05) compared to control (0.81 ± 0.07), and in
SUM225 cells (0.62 ± 0.04 fold, p <0.05) compared to con-
trol (1.06 ± 0.05). In addition, cell migration in DCIS.COM
BCL9 KD was significantly lower (0.2 ± 0.03 fold, p <0.05)
compared to control cells (1.00 ± 0.11, p <0.05). However,
there was no significant reduction in SUM225 BCL9 KD
(0.70 ± 0.23 fold, p <0.05) migration compared to thecontrol (1.00 ± 0.14 fold). The results for MTS assay have
been confirmed using shRNA2 (Additional file 6: Figure
S3B) and for invasion and migration (Additional file 6:
Figure S3C-D). While there was a trend towards a reduc-
tion in migration and invasion for SUM225 using shRNA2,
these results did not reach statistical significance
(Additional file 6: Figure S3D). Furthermore, re-expression
of BCL9 in BCL9 KD DCIS.COM cells using a BCL9-
overexpression lentiviral vector, resulted in a significant
Control BCL9-KD
BCL9
K5
DAPI
A
**
B
K5
SMA
DAPI
C
Control BCL9-KD
S
U
M
22
5
D
C
IS
.C
O
M
Control BCL9-KD
DCIS.COM SUM225
M
ax
im
um
 d
is
ta
nc
e 
of
 in
va
si
on
 (
m
)
M
ax
im
um
 d
is
ta
nc
e 
of
 in
va
si
on
 (
m
)
N
um
be
r 
of
 in
va
si
ve
 a
re
as
 p
er
 s
ec
tio
n
N
um
be
r 
of
 in
va
si
ve
 a
re
as
 p
er
 s
ec
tio
n
BCL9
K19
DAPI
Fig. 5 BCL9-KD inhibits invasion in DCIS cell line mouse intraductal xenograft model (MIND) xenografts. a Immunofluorescent (IF) staining of
BCL9 (red), K5/K19 (green), and 4′,6-diamidino-2-phenylindole (DAPI) (blue) in DCIS.COM (left) and SUM225 (right), control and BCL9-KD MIND
xenografts at 10 and 14 weeks post-intraductal injection, respectively. b IF staining of K5 (red), smooth muscle actin (SMA) (green), and DAPI in
DCIS.COM cells demonstrating how distance of invasion was measured. Scale bars = 50 μm, × 40 magnification. c Bar graphs represent the
maximum distance of invasion and number of invasive lesions in control and BCL9-KD for DCIS.COM and SUM225 MIND xenografts. Data
represent the mean ± standard error of the mean (n = 4, *p <0.05)
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(Additional file 7: Figure S4A-D) (p <0.05).
To examine the role of BCL9 in invasive progression
in vivo, BCL9 KD DCIS.COM and SUM225 cells, and con-
trol cells, were transplanted as MIND xenografts (Fig. 5a).
Glands were collected at 10 weeks post-transplantation for
DCIS.COM, and at 14 weeks for SUM225, and prepared
for IF using antibodies for BCL9 to confirm in vivo KD,
human cytokeratin 5 and 19 (K5 and K19) to detect in vivo
growth of human DCIS-like lesions, SMA to detect the
myoepithelial layer, phospho-histone 3 (phosphoH3) to de-
tect cell proliferation, and cleaved caspase 3 to detect
apoptosis. As shown (Fig. 5a), successful in vivo KD was
achieved in both DCIS.COM and SUM225. The extent of
invasion was analyzed by measuring the maximum dis-
tance traveled by the invasive cells past the myoepithelial
layer of each mammary duct, and by counting the number
of invasive lesions per gland (Fig. 5b). As shown in Fig. 5c,
BCL9 KD DCIS.COM and SUM225 MIND lesions showed
a significant reduction in the maximum distance of inva-
sion (DCIS.COM= 78.0 ± 22.3 μm in KD compared to
302.7 ± 12.4 μm in control and for SUM225 = 75.5 ± 18.9 μm
in KD compared to 338.3 ± 18.8 μm in control; p <0.05) andin the number of invasive lesions per field compared to the
control (DCIS.COM = 1.4 ± 0.5 in KD compared to 4.3
± 0.9 in control and for SUM225 = 3.0 ± 3.0 invasive lesions
in KD compared to 11.7 ± 1.2 invasive lesions in control; p
<0.05). As shown in Fig. 6a, BCL9 KD DCIS.COM and
SUM225 showed a significant reduction in phosphoH3
compared to the control DCIS.COM and SUM225
(DCIS.COM = 3.25 ± 0.01 cells per 500 KD cells com-
pared to 5.25 ± 0.25 cells per 500 control cells counted;
SUM225 = 7.83 ± 0.01 cells per 500 KD cells compared to
21.5 ± 2.36 per 500 control cells counted; p <0.05). How-
ever, there was no change in the number of cleaved caspase
3-positive cells (Fig. 6b). These data demonstrate that BCL9
promotes in vivo cellular proliferation and invasion, while
BCL9 is not involved in cell survival and viability.
BCL9 regulates the expression of EMT biomarkers
Previous studies in colon carcinoma and multiple myeloma
models showed that tumors with BCL9 KD exhibited
altered expression and distribution of mesenchymal
and epithelial markers, vimentin, β-catenin and E-cadherin,
indicative of reduced EMT [11]. Likewise, Deka, J and
Colleagues [42] showed that mice with the conditionally
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Fig. 6 BCL9-KD decreased epithelial cell proliferation in vivo. Immunofluorescent staining of control and BCL9-KD DCIS.COM and SUM225 MIND
xenografts stained with the proliferation marker phospho-histone 3 (phosphoH3) (a) and an apoptotic marker cleaved caspase 3 (b) (green), and
K5/K19 (red), and 4′,6-diamidino-2-phenylindole (DAPI). White arrows point to the cells with positive staining. The bar graphs represent the number
of positive cells per 500 cells; the data represent the mean ± standard error of the mean (n = 4, *p <0.05)
Elsarraj et al. Breast Cancer Research  (2015) 17:128 Page 12 of 21deleted Bcl9/Bcl9l in intestinal cells exposed to a carcino-
gen (dimethylhydrazine followed by DSS) showed higher
expression of both Wnt target genes that regulate EMT
(vimentin, fibronectin and β-catenin) and stem-cell-related
genes such as Sox6 compared to wild type. Based on these
data, we proceeded with assessing the role of BCL9 on the
expression of EMT biomarkers in our DCIS cell lines.
Western blot was performed on cell lysates derived from
DCIS.COM and SUM225 cells that were NT, expressed ascrambled shRNA control, or BCL9 KD using antibodies
for vimentin as a mesenchymal marker and E-cadherin as
an epithelial marker. BCL9 KD in DCIS.COM cells resulted
in a reduction in vimentin and an increase in epithelial
marker E-cadherin (Fig. 7a, Additional file 6: Figure S3A,
and Additional file 8: Figure S5). SUM225 also showed an
increase in E-cadherin, but control cells did not express
vimentin, so as expected, BCL9 KD did not change vimen-
tin expression. To confirm our findings in vivo, IF
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Fig. 7 BCL9 KD reduced the mesenchymal markers and increased the luminal markers in DCIS.COM cell line. a Representative western blot analysis of
cell lysates from non-transduced (NT), control and BCL9-KD DCIS.COM and SUM225 cells blotted with anti-BCL9, anti-vimentin, and anti-E-cadherin
antibodies. β-actin was used as a loading control. The labels show percent change in BCL9-KD protein compared to control. b and
c show immunofluorescent images of control (a-d) and BCL9-KD DCIS.COM (e-h) xenografts stained with vimentin (b) and E-cadherin
(c) (red), and K5 (green), and 4′,6-diamidino-2-phenylindole (DAPI) in (blue). Scale bars =50 μm, × 40 magnification. d Bar graphs of cell
fluorescence intensity units for E-cadherin and vimentin in control and BCL9 KD DCIS.COM cells. Measurements were obtained by ImageJ.
Corrected cell fluorescence was calculated by subtracting the background mean density from the total integrated density. The data represent the
mean ± standard error of the mean (n = 4, *p <0.05)
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SUM225 MIND xenografts, and their controls, using
anti-vimentin, anti-E-cadherin, and anti-K5/K19 anti-
bodies. Images were analyzed using ImageJ for fluores-
cence intensity. As shown in Fig. 7b-d, in our
DCIS.COM MIND xenografts there was a significant
increase in E-cadherin expression in BCL9 KD com-
pared to the control (681,207 ± 198,349 U compared to
120,994 ± 25,258 U; p <0.05) and a significant reduction
in vimentin expression in BCL9 KD compared to
control (44,967 ± 5,402 U compared to 400,345 ± 111,633 U;
p <0.05). DCIS.COM cells generate basal-like DCIS like
lesions in vivo. However, in our SUM225 xenografts, thereControlA
B
Fig. 8 BCL9-KD increased CD24 positive population in DCIS.COM. a Repres
CD24 and CD44 (top), b representative histogram showing changes in CD2
cells (yellow line) compared to isotype control (red line). c Bar graphs show
the data represent the mean ± standard error of the meanwas not a significant reduction in vimentin and or up-
regulation in E-cadherin expression. SUM225 cells
generate luminal-like DCIS lesions in vivo. These data
suggest that BCL9 may have a more significant effect
on the EMT-like phenotype in basal cells compared
to luminal cells. The effects of BCL9 KD on the luminal
marker CD24 and the basal marker CD44 in DCIS.COM
and SUM225 were also assessed by flow cytometry
analysis of NT, control and BCL9 KD cells. As seen in
Fig. 8a-c (dot plot on the top panel and histogram on the
lower panel), BCL9-KD cells showed an increase in the
expression of luminal marker CD24 compared to the con-
trol in DCIS.COM (77.27 % ± 0.20 % vs 90.77 % ± 3.26 %;Isotype
Control
BCL9 -KD
BCL9-KD
C
entative flow analysis of control and BCL9-KD DCIS.COM cells for
4 (left) and CD44 (right) in control (blue line), BCL9-KD DCIS.COM
the percentage of CD24-positive population in BCL9 KD and control,
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not shown). CD44 expression levels did not change in
either cell line, DCIS.COM or SUM225 (Fig. 8b; SUM225
data not shown). These data confirm our previous findings
that BCL9 may contribute to the maintenance of an EMT
program in some but not all cancer cell types.
BCL9 interacts with β-catenin and enhances Wnt/β-catenin
signaling
BCL9 and its homolog BCL9L and pygopus (PYGO)
have been identified as co-activators for Wnt/ β-catenin
transcription in Drosophila and in mammalian cells [11, 27].
To examine BCL9 and β-catenin interactions in our DCIS
cell line models, BCL9 was immunoprecipitated from whole
cell extracts of DCIS.COM and SUM225 cells using
anti-BCL9 antibody, followed by western blot using anti
β-catenin antibody. As shown in Fig. 9a, BCL9 interacts
with β-catenin in both of our DCIS cell lines, DCIS.COM
(Fig 9a, left panel) and SUM225 (Fig 9a, right panel). To0
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reporter activity in DCIS.COM non-transduced (NT), control, and BCL9-KD
(CM). c FopFlash in these cells with control or Wnt3A CM. d STopFlash report
or all combined that were either treated with Wnt3A or control CM. e
mean ± standard error of the mean (n = 3, * p <0.05, letters indicate statisticalexplore whether BCL9 modulates Wnt/β-catenin-mediated
transcription, we utilized the SuperTopFlash (STopflash), a
luciferase reporter assay that measures β-catenin/LEF-TCF-
mediated transcription, along with the FopFlash reporter
with mutated LEF/TCF binding sites as a control. Non-
transduced, control, and BCL9-KD DCIS.COM and
SUM225 cells were transiently transfected along with
STopFlash and FopFlash reporters, and treated with
control or Wnt3A conditioned medium (CM) 4 h after
transfection. Twenty-four hours after transfection, lucifer-
ase activity was measured. As shown in Fig. 9b and c, KD
of BCL9 significantly reduced β-catenin/TCF-mediated
transcription (p <0.05) in DCIS.COM, both in the presence
and absence of Wnt3A stimulation, compared to similarly
treated NT and controls, but not in SUM225 cells with or
without Wnt3a stimulation (data not shown). In order to
assess whether BCL9 enhances β-catenin mediated tran-
scription, we overexpressed BCL9 and constitutively active
β-catenin in human embryonic kidney (HEK) 293 T cells,R
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shown). As expected, constitutively active β-catenin expres-
sion increased transcription, both in the absence and pres-
ence of Wnt3a stimulation, compared to non-transduced
controls (NT; p <0.05; Fig. 9d). Overexpression of BCL9
(BCL9 OE) enhanced β-catenin/TCF-mediated transcrip-
tion induced by Wnt3A by about two-fold compared to
NT control (p <0.05). Furthermore, cells that overex-
pressed both BCL9 and constitutively active β-catenin
showed significantly higher β-catenin/TCF-mediated tran-
scription compared to β-catenin overexpression alone and
in response to Wnt3A stimulation (approximately 1.7-fold
increase; p <0.05). In addition, we analyzed canonical Wnt
activation in BCL9 KD DCIS.COM cells after
re-expression of BCL9 (BCL9-KD/OE). As shown in
Additional file 7: Figure S4E, BCL9 KD/OE showed a
significant increase in reporter activity compared to BCL9
KD with Wnt3a treatment (11.42 +/-0.46 vs. 3.3+/-0.76;
p<0.05) and without wnt3a treatment (1.7+/-0.28 vs
0.6+/-0.13). These data demonstrate that BCL9, by bind-
ing to β-catenin, enhances canonical Wnt activation in the
DCIS.COM cells (a basal cell line). While BCL9 still binds
to β-catenin in SUM225 (luminal HER2 overexpressing)
it does not activate Wnt canonical signaling that can
be assessed by luciferase reporter.
Enhanced BCL9 nuclear expression in DCIS with invasive
component and high risk DCIS
Recent strategies have demonstrated some utility in using
expression of a limited gene set for predicting DCIS recur-
rence; however, the general use of this system is contro-
versial [43]. Thus, finding biomarkers of DCIS high risk is
still a research priority in breast cancer. To evaluate BCL9
as a potential biomarker for DCIS with high risk of recur-
rence, we initially examined the pattern of BCL9 expres-
sion using a tissue microarray (TMA) composed of
samples from eight patients with DCIS (three patients
with DCIS and IDC and five purely with DCIS).
Figure 10a and b illustrate the three patterns of stain-
ing observed: weak cytoplasmic staining (adjacent normal;
Fig. 10a left panel); mixed nuclear and cytoplasmic (Fig. 10a
middle panel and Fig.10b lower panel); and enhanced nu-
clear expression (Fig. 10a right panel and Fig. 10b top
panel). All adjacent normal breast epithelial cells expressed
weak cytoplasmic BCL9 expression (similar to Fig. 10a left
panel). Strikingly, all DCIS with IDC cases exhibited >90 %
enhanced nuclear expression (similar to Fig. 10a right
panel). Interestingly, enhanced BCL9 nuclear expres-
sion was associated with a loss of cytokeratin expres-
sion, which is indicative of EMT (as seen in Fig. 10a;
right panel). We also observed increased expression of
BCL9 in stromal macrophages (Fig. 10a; right panel).
However, the role of BCL9 in stromal macrophages is
beyond the scope of this study. Among the samples frompatients purely with DCIS, comedo or cribriform DCIS
exhibited enhanced BCL9 nuclear expression; those with
papillary DCIS showed mixed nuclear and cytoplasmic
BCL9 expression (data not shown).
As high nuclear BCL9 expression is present in DCIS
with concurrent IDC, it may mean that this pattern pre-
dicts aggressive behavior; however, we do not know
whether the patients with purely DCIS will have recur-
rence, nor do we know whether the lesions were com-
pletely excised, which could of course ensure a favorable
outcome, even if the purely DCIS lesions with nuclear
BCL9 were more aggressive. To begin to address this
question, we examined the pattern of BCL9 expression in
an expanded patient set that included 28 samples from pa-
tients who were diagnosed with DCIS. (Fig. 10c). In this set,
we compared BCL9 localization with pathologic variables
that are known to correlate with aggressive behavior and
high risk for recurrence: nuclear grade, hormone receptor
status and HER2 expression [44]. This analysis showed
that DCIS lesions expressing higher numbers of nuclear
BCL9-positive cells were more likely to be ER-negative
(p = 0.004; Wilcoxon rank sum test), PR-negative
(p = 0.003; Wilcoxon rank-sum test), high nuclear grade
(Spearman correlation = 0.49; p = 0.008), and high HER2-
expressing (Spearman correlation = 0.56; p = 0.002; Fig. 10c).
Based on these data, BCL9 may serve as a future potential
biomarker if validated in a larger dataset of DCIS patients
with known outcome data.
Interestingly, analysis of TCGA data (provisional
TCGA; 959 cases) [24] showed that 26 % of invasive
breast cancers contain BCL9 gene alterations. The ma-
jority of these alterations include amplification (13 %)
and mRNA upregulation (17 %). This is a significant
level of gene alteration when compared to ESR1 (8 %),
ERBB2 (19 %) and BCL9L (5 %) (Additional file 9:
Figure S6A). Furthermore, BCL9 amplification is ob-
served in a significantly higher proportion of invasive
basal breast cancer (BLBC) subtypes compared to the
other subtypes (Additional file 9: Figure S6B-C) [45–46].
Moreover, there is a significant association between
BCL9 gene amplification and mRNA upregulation
(Additional file 9: Figure S6D). These data suggest that
BCL9 may predispose to the development of basal-like
invasive breast cancers. The TCGA data were also ana-
lyzed for the expression of differentially expressed
genes in breast cancers that showed BCL9 upregula-
tion. BCL9 upregulation was defined as BCL9 expres-
sion levels above the range defined by normal samples.
An IPA analysis on the differentially expressed genes
showed Wnt/β-catenin pathway to show a significant
upregulation in BCL9-high compared to BCL9-low
breast cancers (Additional file 10). A list of significant
genes (1,756 downregulated and 980 upregulated) are
listed in the Additional file 11.
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Fig. 10 BCL9 may serve as a biomarker of high risk DCIS. a Immunofluorescence (IF) staining using anti-BCL9 antibody (red), anti-K5/K19 (green),
and counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue) in patient DCIS samples with and without invasion, and in normal adjacent
human breast epithelial cells. b Representative IF images for patient DCIS samples with the above antibodies, demonstrating nuclear (top) and
cytoplasmic (bottom) BCL9 expression patterns. c Statistical analysis of tissue sections from 28 patients purely with DCIS analyzed by IF
using anti-BCL9 antibody. This analysis showed that the percentage of cells expressing nuclear BCL9 was significantly higher in DCIS that
were estrogen receptor (ER)-negative (p = 0.004; Wilcoxon rank sum test), progesterone receptor (PR)-negative (p = 0.003; Wilcoxon rank-sum
test), high human epidermal growth factor receptor 2(HER2) (Spearman correlation = 0.56; p= 0.002), and high nuclear grade (Spearman correlation = 0.49;
p = 0.008). Median percentage (IQR) of cells positive for nuclear BCL9 for ER-positive samples = 8 % (1 %, 40 %); for PR-positive = 8 % (1 %, 35 %);
ER-negative = 90 % (15 %, 95 %); PR-negative = 90 % (15 %, 95 %)
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Canonical Wnt signaling can be constitutively activated in
cancer by a variety of mechanisms including mutations in
adenomatous polyposis coli (APC), Axin, and β-catenin
[47]. These mutations enable β-catenin to escape destruc-
tion and drive oncogenic Wnt signaling [47]. However, inbreast cancer, where mutations in APC or β-catenin are not
commonly reported, BCL9 overexpression may be a mo-
lecular mechanism contributing to aberrant Wnt activation
and progression [11]. The mechanism by which BCL9 is
overexpressed in some cancers is not entirely understood,
but cancer genome analysis via GISTIC reveals copy
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examined [46]. BCL9 resides on chromosome 1q (1q21).
Chromosome 1q amplification is a common finding in
several cancers including breast [48]. BCL9 is a nuclear co-
factor that, by binding to β-catenin and PYGO, modulates
canonical Wnt signaling and promotes β-catenin-mediated
transcription. The formation of a quaternary complex con-
sisting of LEF/TCF, β-catenin, BCL9 and PYGO enhances
β-catenin-dependent Wnt transcriptional activity [35]. In-
deed, BCL9 is recognized as an adaptor that helps PYGO
in recognizing modified histone H3 tails by their plant
homeodomain (PHD) fingers [49]. The human BCL9
and its paralog BCL9L reside on chromosome 1q21
and 11q23.3 respectively. Thus, the molecular regulation
of these two genes may be very different. We did not
find BCL9L upregulation to be associated with inva-
sive progression in our DCIS MIND models. The role
of BCL9L in breast cancer is currently unknown. One
study reported BCL9L to regulate ER transcription by
interaction with Sp1 through the proximal ESR1 gene
promoter and to be highly expressed in patients with
ER-positive breast cancers [37]. The exact role of BCL9 vs
BCL9L in normal mammary gland development has not
been studied.
We identified BCL9 by analysis of molecular profiling
of DCIS at distinct stages of in situ to invasive transition.
Our initial findings suggest that BCL9 expression and
activity are important risk factors for breast cancer progres-
sion. This is based on the enhanced nuclear expression of
BCL9 in DCIS epithelia that progress to invasion. Silencing
of BCL9 in our invasive DCIS cell line led to in vivo and
in vitro inhibition of both cell growth and invasion, and
downregulation of vimentin, a biomarker of EMT. The role
of BCL9 in the progression of other types of cancers has
been reported previously. However, to our knowledge, there
are currently no data on the role of BCL9 in breast cancer
progression. Mani and colleagues [11] showed that KD of
BCL9 by shRNA in a colon cancer cell line (colo320) and a
multiple myeloma cell line (MM1S) caused a significant re-
duction in proliferation and colony formation. Overexpres-
sion of BCL9 increased colo320 and MM1S migration in
transwell migration assays and in vitro Matrigel-coated in-
vasion assays. Immunocompromised mice injected with
colo320 KD of BCL9 showed significant increase in survival
and reduced lung metastasis. Likewise, mice injected with
MM1S cells KD BCL9 also showed improved survival and
reduced metastasis to the long bones, spine, and head.
BCL9 KD tumors also showed reduced EMT markers
such as vimentin, E-cadherin and β-catenin.
We demonstrated that BCL9 KD resulted in suppres-
sion of Wnt signaling as assessed by TOP-FLASH Wnt
reporter assays in our basal DCIS cell line (DCIS.COM),
while BCL9 KD in SUM225 (luminal HER2 overexpress-
ing) did not affect the canonical Wnt signaling. Thisresult may indicate that the canonical Wnt pathway is
involved in the progression of certain subtypes of breast
cancer i.e., basal subtypes. This observation is interesting
because the TCGA breast cancer data shows that BCL9
is significantly amplified in basal subtypes of breast
cancers [46, 50]. However, there is also the possibility
that TopFlash used in our study did not detect Wnt ac-
tivity because this reporter does not detect all transcrip-
tional effects in Wnt signaling.
Our studies also suggest that BCL9 may serve as a fu-
ture biomarker of high-risk DCIS if validated in a large
dataset of DCIS patients with known outcome. By ana-
lysis of 28 DCIS patient samples, we demonstrated that
DCIS lesions expressing higher nuclear BCL9 (percent-
age of cells expressing nuclear BCL9) were more likely
to be ER-negative, PR-negative, high nuclear grade, and
high in HER2 expression. These characteristics are asso-
ciated with higher recurrence rate in DCIS [44].Conclusion
Collectively, the findings in this study suggest that BCL9,
by enhancement of canonical Wnt signaling and initiating
an EMT program, serves as an important molecular driver
in invasive transition of human DCIS. Therefore, BCL9
may serve as a potential future biomarker of high-risk
DCIS and as a therapeutic target for prevention of IDC.Additional files
Additional file 1: Table S1. List of antibodies and sources for use in
immunofluorescent staining, co-immunoprecipitation, western analysis,
and FACS analysis. (PDF 245 kb)
Additional file 2: Figure S1. Majority of SUM225 and DCIS.COM cells
were epithelial cell adhesion molecule (EPCAM)-positive by flow analysis.
Representative flow analysis of (A) SUM225 (left) and DCIS.COM cells (right)
for EpCAM (black line) compared to isotype control (gray line) showed that
95 % of SUM225 cells and 99 % of DCIS.COM cells were EPCAM-positive. B
Histogram overlaying SUM225 and DCIS.COM EPCAM positive cells. C Flow
analysis for EPCAM positive cells in BCL9 KD (gray line) and control (black line)
SUM225 cells at 6 weeks post intraductal injection. D Bar graphs representing
EPCAM expression levels in BCL9 KD and Control cells show no statistically
significant differences among the groups (n = 3). (PDF 417 kb)
Additional file 3: Differentially expressed genes in DCIS.COM and
SUM225 mouse intraductal xenograft model (MIND) xenografts
during transition from 2 to 6 weeks. Significance analysis for
microarrays (SAM) software was utilized to determine differentially expressed
genes between the 2- to 6-week time point in both DCIS.COM and SUM225
cell lines. The cutoff for significance was determined by <5 % false discovery
rate. Two-class unpaired SAM analysis generated a
list of significant genes and fold-change values between 2 and 6 weeks
in DCIS.COM (18,590 downregulated; 10,227 upregulated) and SUM225
(19,953 downregulated and 14,691 upregulated). (XLSX 3297 kb)
Additional file 4: Wnt-pathway-specific genes differentially
expressed in ductal carcinoma in situ DCIS.COM and SUM225 mouse
intraductal xenograft model (MIND) xenografts during transition from 2
to 6 weeks. Genes significantly differentially expressed between the 2- to
6-week time point in both DCIS.COM and SUM225 cell lines were further
analyzed using Ingenuity Pathway Analysis® (IPA). The Wnt/β-catenin
canonical pathway was identified as a significantly upregulated pathway
Elsarraj et al. Breast Cancer Research  (2015) 17:128 Page 19 of 21in both cell line MIND xenografts during transition from 2 to 6 weeks.
(XLS 48 kb)
Additional file 5: Figure S2. BCL9 showed increased nuclear expression,
while BCL9L expression remained cytoplasmic during ductal carcinoma in situ
(DCIS) invasive transition. A Immunofluorescence staining of BCL9 (red; top
panel), BCL9L (red; bottom panel), K5/K19 (green), and Hoechst (blue) in a
primary sample that represents: adjacent normal glands (left), DCIS lesions
(middle), and invasive ductal carcinoma (IDC) (right). BCL9 and BCL9L are
conjugated to Alexa-Fluor 594 (red) and K5/K19 were conjugated to Alexa-
Fluor 488 (green). Nuclei were counterstained with Hoechst. Scale bars 50 μm,
× 40 objective was used. B, C RT-qPCR of BCL9 and BCL9L mRNA in epithelial
cell adhesion molecule (EpCAM)-positive epithelial cells sorted from SUM225
(B) and DCIS.COM (C) mouse intraductal xenograft model (MIND) xenografts
at 2, 6, and 10 weeks post-intraductal injection. The bar graphs represent fold
change normalized to 2 weeks. Data are mean values ± standard error of the
mean (n = 3, *p <0.05). D Representative western blot analysis of cell lysates
from control and BCL9-KD-SUM225 and DCIS.COM blotted with anti-BCL9,
and anti-BCL9L antibodies. β-actin was used as a loading control.
The analysis showed no change in BCL9L protein levels in BCL9-KD
cells compared to control cells. (PDF 5012 kb)
Additional file 6: Figure S3. MTS, migration and invasion assays in
ductal carcinoma in situ (DCIS) BCL9-KD cells with shRNA 2. A Western blot
analysis using anti-BCL9, anti-vimentin, anti-E-cadherin antibodies, and
anti-β-actin antibody as a loading control. B MTS assays of scrambled
control 2 (control 2) and BCL9-KD 2 in DCIS.COM (left bar graph) and
SUM225 (right bar graph). Bar graphs represent mean absorbance at 490
nm normalized to control ± standard error of the mean (SEM) (n = 3, *P <0.05).
C, D Representative images of the migration and invasion assays. Bar graph
represent percent area of cells migrated (left) and invaded (right) under the
membrane after 24 h for DCIS.com and 96 h for SUM225. Invasion and
migration were determined by ImageJ analysis of microscopic images
per sample, the data are mean values normalized to control ± SEM
(n = 3, *P <0.05). E STopFlash and FopFlash reporter activity in DCIS.COM
control 2, and BCL9-KD 2, which were either treated with Wnt3A
or control conditioned medium (CM). Data represent mean ± SEM
(n = 3, *P <0.05). (PDF 650 kb)
Additional file 7: Figure S4. MTS, migration and invasion assays in
DCIS.COM cells that were previously transduced with scrambled control
(Control) or BCL9 KD shRNA. The control cells and BCL9 KD cells were
re-transduced with empty vector (EV), BCL9 overexpression (BCL9-OE)
and BCL9 KD. BCL9-OE was achieved by transduction using the
PCDH-BCL9 (BCL9-OE) acquired from Dr. Carrasco [11]. A Western blot
analysis was performed using anti-BCL9, anti-vimentin, anti-E-cadherin
antibodies, and anti-β-actin as a loading control. B MTS assay on control cells
transduced with EV (control + EV), or BCL9-OE (control + BCL9-OE), BCL9-KD
transduced with EV (BCL9 KD + EV), and BCL9-KD transduced with BCL9-OE
(BCL9 KD + BCL9-OE). Bar graphs represent mean absorbance at 490 nm
normalized to control ± standard error of the mean (SEM) (n = 6).
C, D Representative images of the migration and invasion assays. Bar
graph represents percent area of cells migrated (left) and invaded
(right) under the membrane after 24 h. Invasion and migration were
determined by ImageJ analysis of microscopic images per sample, the
data are mean values normalized to control ± SEM (n = 3). E TopFlash and
FopFlash reporter activity in DCIS.COM transduced as above that were either
treated with Wnt3A or control conditioned medium (CM). Data represent
mean ± SEM (n = 3, letters indicate statistically significant difference).
(PDF 964 kb)
Additional file 8: Figure S5. Bar graphs represent densitometry of
BCL9, E-cadherin, and vimentin in non-transduced (NT), control, and BCL9 KD
DCIS.COM (A) (n = 4), and BCL9 and E-cadherin in NT, control, and BCL9 KD
SUM225 (B) (n = 3). Data represent mean ± standard error of the mean
(*P <0.05). (PDF 492 kb)
Additional file 9: Figure S6. A significant proportion of breast cancers
showed BCL9 gene alteration. A The Cancer Genome Atlas (TCGA) provisional
data showed that 26 % of invasive breast cancers (total of 965 cases) contained
a genetic alteration in the BCL9 gene; the majority of these consisted of gene
amplification and mRNA upregulation. This was a significant level of genetic
alteration when compared to ERBB2 (19 %), ESR1 (8 %) and BCL9L (5 %). B BCL9
gene alterations across all cancers. The BCL9 gene was altered in many cancersincluding breast, liver and bladder. The arrow points to invasive breast cancers
showing 14 % gene alteration (135 in 962 cases). C, D TCGA data showed that
a significantly higher proportion of basal breast cancers contained BCL9
genomic amplification compared to the other subtypes (total of 825 cases).
E The gene expression data were available as z scores. Diploid classification was
used to identify median gene expression value, and this value was used as the
cutoff for dichotomizing gene expression as low (<= median) or high
(>median) for BCL9 expression. Contingency tables were created for
diploid vs amplified or gain vs amplified against low or high BCL9
expression. Chi-square analysis indicated significant association
between BCL9 amplification and high levels of BCL9 gene expression
compared to diploid samples. (PDF 3138 kb)
Additional file 10: Analysis of The Cancer Genome Atlas (TCGA) data
showing canonical Wnt pathways genes expressed in BCL9-high versus
BCL9-low tumors. TCGA breast cancer samples with BCL9 levels above
the range defined by normal samples were labeled upregulated in
cancer (414 samples). The significant differentially expressed genes
from TCGA analysis of BCL9-high versus BCL9-low tumors were analyzed in
Ingenuity Pathway Analysis (IPA) and the canonical pathways with a p value
≤0.05 were obtained. (XLS 124 kb)
Additional file 11: Analysis of the The Cancer Genome Atlas (TCGA)
data showed differentially expressed genes in BCL9-high versus
BCl9-low tumors. Differential gene expression was performed between
TCGA breast cancer samples with a normal range of BCL9 and samples
with upregulated BCL9. A list of significant genes (1,756 down regulated
980 upregulated) was obtained with a threshold of a false discovery rate
≥0.05 and log fold change 0.26. (XLSX 1492 kb)
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